New Bipartisan Bill Aims to Expand Lifesaving Prostate Cancer Care for Veterans Jump To Events Awareness Education Support Community Advocacy More Veterans have made extraordinary sacrifices in service to our country—and they deserve access to the best possible care when facing prostate cancer.That's why ZERO Prostate Cancer is applauding the introduction of the bipartisan Precision Oncology Program for Cancer of the Prostate (POPCaP) Authorization Act, legislation that would permanently authorize and expand a groundbreaking Department of Veterans Affairs program delivering precision medicine to veterans diagnosed with prostate cancer. The bill was introduced in the Senate by Veterans' Affairs Committee Chairman Jerry Moran (R-KS) and in the House by Representatives Greg Murphy, MD (R-NC), and Herb Conaway, MD (D-NC).Prostate cancer is the most commonly diagnosed cancer among veterans, and military service-related exposures put many at increased risk. African American veterans face an even greater burden, experiencing prostate cancer diagnosis and mortality rates that are approximately twice those of their peers.The POPCaP Authorization Act would help address these disparities by expanding access to precision oncology, genetic testing, and clinical trials through the creation of seven new Centers of Excellence across the VA system. By bringing advanced, personalized treatment options closer to veterans nationwide, the legislation has the potential to improve outcomes while advancing research that could benefit all men diagnosed with prostate cancer.ZERO Prostate Cancer is urging Congress to move quickly to pass this important legislation. Investing in innovative care for veterans not only honors their service—it also drives research and medical breakthroughs that can improve prostate cancer care for everyone.To learn more about the legislation and ZERO's advocacy efforts, visit ZERO Prostate Cancer's press release.
Veterans have made extraordinary sacrifices in service to our country—and they deserve access to the best possible care when facing prostate cancer.That's why ZERO Prostate Cancer is applauding the introduction of the bipartisan Precision Oncology Program for Cancer of the Prostate (POPCaP) Authorization Act, legislation that would permanently authorize and expand a groundbreaking Department of Veterans Affairs program delivering precision medicine to veterans diagnosed with prostate cancer. The bill was introduced in the Senate by Veterans' Affairs Committee Chairman Jerry Moran (R-KS) and in the House by Representatives Greg Murphy, MD (R-NC), and Herb Conaway, MD (D-NC).Prostate cancer is the most commonly diagnosed cancer among veterans, and military service-related exposures put many at increased risk. African American veterans face an even greater burden, experiencing prostate cancer diagnosis and mortality rates that are approximately twice those of their peers.The POPCaP Authorization Act would help address these disparities by expanding access to precision oncology, genetic testing, and clinical trials through the creation of seven new Centers of Excellence across the VA system. By bringing advanced, personalized treatment options closer to veterans nationwide, the legislation has the potential to improve outcomes while advancing research that could benefit all men diagnosed with prostate cancer.ZERO Prostate Cancer is urging Congress to move quickly to pass this important legislation. Investing in innovative care for veterans not only honors their service—it also drives research and medical breakthroughs that can improve prostate cancer care for everyone.To learn more about the legislation and ZERO's advocacy efforts, visit ZERO Prostate Cancer's press release.
